LP
MLTX icon

Longaeva Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Longaeva Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
161,557
-248,443
-61% -$4.5M 0.07% 222
2026
Q1 		$7.64M Buy
+410,000
New +$6.79M 0.28% 84

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Longaeva Partners's MLTX Position: Q2 2026 in Review

Longaeva Partners reduced its MoonLake Immunotherapeutics (MLTX) stake by 61% in Q2 2026, selling an estimated $4.5M and leaving 161,557 shares worth $3.15M. The position accounts for 0.07% of the portfolio, ranked #222.

Longaeva Partners first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.64M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Longaeva Partners held 161,557 shares of MoonLake Immunotherapeutics worth $3.15M as of Q2 2026.
  • Longaeva Partners sold 248,443 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $4.5M.
  • MoonLake Immunotherapeutics made up 0.07% of Longaeva Partners's portfolio in Q2 2026, its #222 holding.
  • Longaeva Partners first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Longaeva Partners's MoonLake Immunotherapeutics position peaked at $7.64M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.